By Barbara Obstoj-Cardwell. Editor
Regulatory news last week included the US Food and Drug Administration a(FDA) approving UK pharma major GSK’s new myelofibrosis drug Ojjaara (momelotinib) with a wider indication than what hade been expected. The US Federal Commission (FTC) issued a policy on the listing of patents in the FDA’S Orange Book. Last Tuesday, Chinese biotech BeiGene revealed that Swiss pharma giant Novartis has pulled out of a second collaboration, this time regarding time regarding Tevimbra (tislelizumab). Also of note on the research front, US CNS specialist Relmada Therapeutics released positive Phase III results for its REL-1017 as a treatment for major depressive disorder (MDD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze